The DOI matches its Crossref record; 90 of the 90 references it cites were found in a registry or an index.
American Society of Clinical Oncology/American Society of Hematology Clinical Practice Guideline Update on the Use of Epoetin and Darbepoetin in Adult Patients With Cancer
Abstract
Purpose: To update American Society of Clinical Oncology/American Society of Hematology recommendations for use of erythropoiesis-stimulating agents (ESAs) in patients with cancer. Methods: An Update Committee reviewed data published between January 2007 and January 2010. MEDLINE and the Cochrane Library were searched. Results: The literature search yielded one new individual patient data analysis and four literature-based meta-analyses, two systematic reviews, and 13 publications reporting new results from randomized controlled trials not included in prior or new reviews. Recommendations: For patients undergoing myelosuppressive chemotherapy who have a hemoglobin (Hb) level less than 10 g/dL, the Update Committee recommends that clinicians discuss potential harms (eg, thromboembolism, shorter survival) and benefits (eg, decreased transfusions) of ESAs and compare these with potential harms (eg, serious infections, immune-mediated adverse reactions) and benefits (eg, rapid Hb improvement) of RBC transfusions. Individual preferences for assumed risk should contribute to shared decisions on managing chemotherapy-induced anemia. The Committee cautions against ESA use under other circumstances. If used, ESAs should be administered at the lowest dose possible and should increase Hb to the lowest concentration possible to avoid transfusions. Available evidence does not identify Hb levels ≥ 10 g/dL either as thresholds for initiating treatment or as targets for ESA therapy. Starting doses and dose modifications after response or nonresponse should follow US Food and Drug Administration–approved labeling. ESAs should be discontinued after 6 to 8 weeks in nonresponders. ESAs should be avoided in patients with cancer not receiving concurrent chemotherapy, except for those with lower risk myelodysplastic syndromes. Caution should be exercised when using ESAs with chemotherapeutic agents in diseases associated with increased risk of thromboembolic complications. Table 1 lists detailed recommendations. This guideline was developed through a collaboration between the American Society of Clinical Oncology and the American Society of Hematology and has been published jointly by invitation and consent in both Journal of Clinical Oncology and Blood. Copyright © 2010 American Society of Clinical Oncology and American Society of Hematology. All rights reserved. No part of this document may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without written permission by the American Society of Clinical Oncology or the American Society of Hematology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeting HIF-1 for cancer therapy
Semenza, G. L. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1187 · Cited by 6,717
A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease
Pfeffer, M. A., Burdmann, E. A., Chen, C.-Y., Cooper, M. E., de Zeeuw, D., Eckardt, K.-U., Feyzi, J. M., Ivanovich, P., Kewalramani, R., Levey, A. S., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0907845 · Cited by 2,096
Yellen, S. B., Cella, D. F., Webster, K., Blendowski, C., & Kaplan, E. (1997) · Journal of Pain and Symptom Management · doi:10.1016/s0885-3924(96)00274-6 · Cited by 1,964
Cheson, B. D. (2006) · Blood · doi:10.1182/blood-2005-10-4149 · Cited by 1,580
Henke, M., Laszig, R., Rübe, C., Schäfer, U., Haase, K.-D., Schilcher, B., Mose, S., Beer, K. T., Burger, U., Dougherty, C., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14567-9 · Cited by 1,250
Littlewood, T. J., Bajetta, E., Nortier, J. W. R., Vercammen, E., Rapoport, B., & for the Epoetin Alfa Study Group (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.11.2865 · Cited by 974
Cella, D., Eton, D. T., Lai, J.-S., Peterman, A. H., & Merkel, D. E. (2002) · Journal of Pain and Symptom Management · doi:10.1016/s0885-3924(02)00529-8 · Cited by 808
Bennett, C. L. (2008) · JAMA · doi:10.1001/jama.299.8.914 · Cited by 731
Self-citationLeyland-Jones, B., Semiglazov, V., Pawlicki, M., Pienkowski, T., Tjulandin, S., Manikhas, G., Makhson, A., Roth, A., Dodwell, D., Baselga, J., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.150 · Cited by 668
American Society of Clinical Oncology Guidance Statement: The Cost of Cancer Care
Meropol, N. J., Schrag, D., Smith, T. J., Mulvey, T. M., Langdon, R. M., Blum, D., Ubel, P. A., & Schnipper, L. E. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.1183 · Cited by 638
Bohlius, J., Schmidlin, K., Brillant, C., Schwarzer, G., Trelle, S., Seidenfeld, J., Zwahlen, M., Clarke, M., Weingart, O., Kluge, S., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60502-x · Cited by 597
Self-citationErythropoietin has a mitogenic and positive chemotactic effect on endothelial cells.
Anagnostou, A., Lee, E. S., Kessimian, N., Levinson, R., & Steiner, M. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.15.5978 · Cited by 569
Bohlius, J., Wilson, J., Seidenfeld, J., Piper, M., Schwarzer, G., Sandercock, J., Trelle, S., Weingart, O., Bayliss, S., Djulbegovic, B., et al. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj189 · Cited by 548
Self-citationSecondary analysis of the CHOIR trial epoetin-α dose and achieved hemoglobin outcomes
Szczech, L. A., Barnhart, H. X., Inrig, J. K., Reddan, D. N., Sapp, S., Califf, R. M., Patel, U. D., & Singh, A. K. (2008) · Kidney International · doi:10.1038/ki.2008.295 · Cited by 526
Cella, D., Hahn, E. A., & Dineen, K. (2002) · Quality of Life Research · doi:10.1023/a:1015276414526 · Cited by 523
The Definition of Anemia in Older Persons
Izaks, G. J. (1999) · JAMA · doi:10.1001/jama.281.18.1714 · Cited by 495
Oxygenation status of malignant tumors: Pathogenesis of hypoxia and significance for tumor therapy
VAUPEL, P. (2001) · Seminars in Oncology · doi:10.1016/s0093-7754(01)90210-6 · Cited by 479
Polycythemia vera: myths, mechanisms, and management
Spivak, J. L. (2002) · Blood · doi:10.1182/blood-2001-12-0349 · Cited by 463
Self-citationWright, J. R., Ung, Y. C., Julian, J. A., Pritchard, K. I., Whelan, T. J., Smith, C., Szechtman, B., Roa, W., Mulroy, L., Rudinskas, L., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.1514 · Cited by 428
Rizzo, J. D., Lichtin, A. E., Woolf, S. H., Seidenfeld, J., Bennett, C. L., Cella, D., Djulbegovic, B., Goode, M. J., Jakubowski, A. A., Lee, S. J., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.07.177 · Cited by 417
Self-citationErythropoietin or darbepoetin for patients with cancer
Tonia, T., Mettler, A., Robert, N., Schwarzer, G., Seidenfeld, J., Weingart, O., Hyde, C., Engert, A., & Bohlius, J. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003407.pub5 · Cited by 392
Self-citationRole of red blood cells in thrombosis
Andrews, D. A., & Low, P. S. (1999) · Current Opinion in Hematology · doi:10.1097/00062752-199903000-00004 · Cited by 349
Brines, M., & Cerami, A. (2008) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2008.02024.x · Cited by 333
Rizzo, J. D., Somerfield, M. R., Hagerty, K. L., Seidenfeld, J., Bohlius, J., Bennett, C. L., Cella, D. F., Djulbegovic, B., Goode, M. J., Jakubowski, A. A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.3396 · Cited by 327
Self-citationÖsterborg, A., Brandberg, Y., Molostova, V., Iosava, G., Abdulkadyrov, K., Hedenus, M., & Messinger, D. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.08.131 · Cited by 310
Anti-Epo receptor antibodies do not predict Epo receptor expression
Elliott, S., Busse, L., Bass, M. B., Lu, H., Sarosi, I., Sinclair, A. M., Spahr, C., Um, M., Van, G., & Begley, C. G. (2006) · Blood · doi:10.1182/blood-2005-10-4066 · Cited by 305
Intravascular flow decreases erythrocyte consumption of nitric oxide
Liao, J. C., W. Hein, T., Vaughn, M. W., Huang, K.-T., & Kuo, L. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.15.8757 · Cited by 305
Effects of erythropoietin on platelet reactivity and thrombopoiesis in humans
Stohlawetz, P. J., Dzirlo, L., Hergovich, N., Lackner, E., Mensik, C., Eichler, H. G., Kabrna, E., Geissler, K., & Jilma, B. (2000) · Blood · doi:10.1182/blood.v95.9.2983.009k27_2983_2989 · Cited by 293
Do Erythropoietin Receptors on Cancer Cells Explain Unexpected Clinical Findings?
Henke, M., Mattern, D., Pepe, M., Bézay, C., Weissenberger, C., Werner, M., & Pajonk, F. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.2737 · Cited by 240
Glaspy, J., Crawford, J., Vansteenkiste, J., Henry, D., Rao, S., Bowers, P., Berlin, J. A., Tomita, D., Bridges, K., & Ludwig, H. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605498 · Cited by 237
(2008) · Cited by 225
Seidenfeld, J., Piper, M., Flamm, C., Hasselblad, V., Armitage, J. O., Bennett, C. L., Gordon, M. S., Lichtin, A. E., Wade, J. L., Woolf, S., et al. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.16.1204 · Cited by 222
Self-citationSmith, R. E., Aapro, M. S., Ludwig, H., Pintér, T., Šmakal, M., Ciuleanu, T. E., Chen, L., Lillie, T., & Glaspy, J. A. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.2885 · Cited by 211
Witzig, T. E., Silberstein, P. T., Loprinzi, C. L., Sloan, J. A., Novotny, P. J., Mailliard, J. A., Rowland, K. M., Alberts, S. R., Krook, J. E., Levitt, R., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.020 · Cited by 209
Greenberg, P. L., Sun, Z., Miller, K. B., Bennett, J. M., Tallman, M. S., Dewald, G., Paietta, E., van der Jagt, R., Houston, J., Thomas, M. L., et al. (2009) · Blood · doi:10.1182/blood-2009-03-211797 · Cited by 208
Osterborg, A., Boogaerts, M., Cimino, R., Essers, U., Holowiecki, J., Juliusson, G., Jager, G., Najman, A., & Peest, D. (1996) · Blood · doi:10.1182/blood.v87.7.2675.bloodjournal8772675 · Cited by 202
Hedenus, M., Birgegård, G., Näsman, P., Ahlberg, L., Karlsson, T., Lauri, B., Lundin, J., Lärfars, G., & Österborg, A. (2007) · Leukemia · doi:10.1038/sj.leu.2404562 · Cited by 198
Tonelli, M., Hemmelgarn, B., Reiman, T., Manns, B., Reaume, M. N., Lloyd, A., Wiebe, N., & Klarenbach, S. (2009) · Canadian Medical Association Journal · doi:10.1503/cmaj.090470 · Cited by 197
Prediction of response to erythropoietin treatment in chronic anemia of cancer [see comments]
Ludwig, H., Fritz, E., Leitgeb, C., Pecherstorfer, M., Samonigg, H., & Schuster, J. (1994) · Blood · doi:10.1182/blood.v84.4.1056.1056 · Cited by 196
Bastit, L., Vandebroek, A., Altintas, S., Gaede, B., Pintér, T., Suto, T. S., Mossman, T. W., Smith, K. E., & Vansteenkiste, J. F. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.4620 · Cited by 195
Erythropoietin for anaemia in cancer patients
Abels, R. (1993) · European Journal of Cancer · doi:10.1016/s0959-8049(05)80281-3 · Cited by 185
Lundby, C., Thomsen, J. J., Boushel, R., Koskolou, M., Warberg, J., Calbet, J. A. L., & Robach, P. (2007) · The Journal of Physiology · doi:10.1113/jphysiol.2006.122689 · Cited by 174
yndromes, I. T. C. O. S. T. G. R. R. I. M. Y. S. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.01085.x · Cited by 174
Wilson, J., Yao, G., Raftery, J., Bohlius, J., Brunskill, S., Sandercock, J., Bayliss, S., Moss, P., Stanworth, S., & Hyde, C. (2007) · Health Technology Assessment · doi:10.3310/hta11130 · Cited by 173
Self-citationThomas, G., Ali, S., Hoebers, F. J. P., Darcy, K. M., Rodgers, W. H., Patel, M., Abulafia, O., Lucci, J. A., & Begg, A. C. (2008) · Gynecologic Oncology · doi:10.1016/j.ygyno.2007.10.011 · Cited by 169
Pedrazzoli, P., Farris, A., Del Prete, S., Del Gaizo, F., Ferrari, D., Bianchessi, C., Colucci, G., Desogus, A., Gamucci, T., Pappalardo, A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.2051 · Cited by 168
Circadian rhythm of erythropoietin in human serum
WIDE, L. E., And, C. B., & Birgegarrd, G. (1989) · British Journal of Haematology · doi:10.1111/j.1365-2141.1989.tb07657.x · Cited by 158
Serum erythropoietin in humans at high altitude and its relation to plasma renin
Milledge, J. S., & Cotes, P. M. (1985) · Journal of Applied Physiology · doi:10.1152/jappl.1985.59.2.360 · Cited by 158
Bohlius, J., Schmidlin, K., Brillant, C., Schwarzer, G., Trelle, S., Seidenfeld, J., Zwahlen, M., Clarke, M. J., Weingart, O., Kluge, S., et al. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007303.pub2 · Cited by 155
Self-citationYoung, A., Chapman, O., Connor, C., Poole, C., Rose, P., & Kakkar, A. K. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.106 · Cited by 150
Thalidomide- and Lenalidomide-Associated Thromboembolism Among Patients With Cancer
Bennett, C. L., Angelotta, C., Yarnold, P. R., Evens, A. M., Zonder, J. A., Raisch, D. W., & Richardson, P. G. G. (2006) · JAMA · doi:10.1001/jama.296.21.2558-c · Cited by 149
Self-citationUm, M., Gross, A. W., & Lodish, H. F. (2006) · Cellular Signalling · doi:10.1016/j.cellsig.2006.08.014 · Cited by 147
Macciò, A., Madeddu, C., Massa, D., Mudu, M. C., Lusso, M. R., Gramignano, G., Serpe, R., Melis, G. B., & Mantovani, G. (2005) · Blood · doi:10.1182/blood-2005-01-0160 · Cited by 144
Streja, E., Kovesdy, C. P., Greenland, S., Kopple, J. D., McAllister, C. J., Nissenson, A. R., & Kalantar‐Zadeh, K. (2008) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2008.05.029 · Cited by 141
Moyo, V. M., Lefèbvre, P., Duh, M. S., Yektashenas, B. H., & Mundle, S. D. (2008) · Annals of Hematology · doi:10.1007/s00277-008-0450-7 · Cited by 140
Confronting Racial and Ethnic Disparities in Health Care
Hood, R. G. (2001) · Academic Medicine · doi:10.1097/00001888-200106000-00006 · Cited by 138
Impact of epoetin β on quality of life in patients with malignant disease
and the Epoetin β QOL Working Group, Boogaerts, M. A., Coiffier, B., & Kainz, C. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6600801 · Cited by 119
Machtay, M. X., Pajak, T. F., Suntharalingam, M., Shenouda, G., Hershock, D. M., Stripp, D. C. H., Cmelak, A. J., Schulsinger, A., & Fu, K. K. (2007) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2007.04.063 · Cited by 114
Pirker, R., Ramlau, R., Schuette, W., Zatloukal, P., Ferreira, I., Lillie, T., & Vansteenkiste, J. F. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.0748 · Cited by 114
Overproduction of platelet microparticles in cyanotic congenital heart disease with polycythemia
Horigome, H., Hiramatsu, Y., Shigeta, O., Nagasawa, T., & Matsui, A. (2002) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(02)01718-7 · Cited by 109
Racial and Ethnic Disparities in Care: The Perspectives of Cardiologists
Lurie, N., Fremont, A., Jain, A. K., Taylor, S. L., McLaughlin, R., Peterson, E., Kong, B. W., & Ferguson, T. B. (2005) · Circulation · doi:10.1161/01.cir.0000157738.12783.71 · Cited by 109
Um, M., & Lodish, H. F. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m510943200 · Cited by 107
Canon, J.-L. R., Vansteenkiste, J., Bodoky, G., Mateos, M., Bastit, L., Ferreira, I., Rossi, G., & Amado, R. G. (2006) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djj053 · Cited by 103
Razzouk, B. I., Hord, J. D., Hockenberry, M. J., Hinds, P. S., Feusner, J. H., Williams, D., & RACKOFF, W. R. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.4371 · Cited by 98
Pharmacokinetics and pharmacodynamics of epoetin alfa once weekly and three times weekly
Cheung, W. K., Minton, N. A., & Gunawardena, K. A. (2001) · European Journal of Clinical Pharmacology · doi:10.1007/s002280100324 · Cited by 96
Brown, W. M., Maxwell, P., Graham, A. N. J., Yakkundi, A., Dunlop, E. A., Shi, Z., Johnston, P. G., & Lappin, T. R. J. (2006) · Stem Cells · doi:10.1634/stemcells.2006-0687 · Cited by 95
Increased plasma viscosity as a reason for inappropriate erythropoietin formation.
Singh, A. P., Eckardt, K., Zimmermann, A., Götz, K.-H., Hamann, M., Ratcliffe, P. J., Kurtz, A., & Reinhart, W. H. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116178 · Cited by 94
Stone, W. J., Gräber, S. E., Krantz, S. B., Dessypris, E. N., O’Neil, V. L., Olsen, N. J., & Pincus, T. (1988) · The American Journal of the Medical Sciences · doi:10.1097/00000441-198809000-00005 · Cited by 93
Grote, T. H., Yeilding, A., Castillo, R., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.8507 · Cited by 85
Erythropoietin as an adjuvant treatment with (chemo) radiation therapy for head and neck cancer
Lambin, P., Ramaekers, B. L. T., van Mastrigt, G. A. P. G., van den Ende, P. L. A., de Jong, J., Ruysscher, D. D., & Pijls-Johannesma, M. C. G. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006158.pub2 · Cited by 78
Erythropoietin for patients with malignant disease
Bohlius, J., Langensiepen, S., Schwarzer, G., Seidenfeld, J., Piper, M., Bennet, C., & Engert, A. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003407.pub2 · Cited by 78
Self-citationHershman, D. L., Buono, D. L., Malin, J. L., McBride, R. B., Tsai, W. Y., & Neugut, A. I. (2009) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djp387 · Cited by 74
Ross, S. D., Allen, I. E., Probst, C. A., Sercus, B., Crean, S. M., & Ranganathan, G. (2007) · The Oncologist · doi:10.1634/theoncologist.12-10-1264 · Cited by 70
Quality‐of‐life and health benefits of early treatment of mild anemia
Straus, D. J., Testa, M. A., Sarokhan, B. J., Czuczman, M. S., Tulpule, A., Turner, R. R., & Riggs, S. A. (2006) · Cancer · doi:10.1002/cncr.22221 · Cited by 67
Keithi-Reddy, S. R., Addabbo, F., Patel, T. V., Mittal, B. V., Goligorsky, M. S., & Singh, A. K. (2008) · Kidney International · doi:10.1038/ki.2008.245 · Cited by 62
Hoskin, P., Robinson, M., Slevin, N. J., Morgan, D., Harrington, K. J., & Gaffney, C. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.3693 · Cited by 58
Mundle, S. D., Lefèbvre, P., Vekeman, F., Duh, M. S., Rastogi, R., & Moyo, V. M. (2009) · Cancer · doi:10.1002/cncr.24090 · Cited by 57
Paragh, G., Kumar, S., Rákosy, Z., Choi, S.-C., Xu, X., & Ács, G. (2009) · American Journal Of Pathology · doi:10.2353/ajpath.2009.080592 · Cited by 44
Erythropoietin use and abuse: When physiology and pharmacology collide.
Spivak, J. L. (2001) · PubMed · Cited by 42
Self-citationMiller, C. P., Lowe, K. A., Valliant‐Saunders, K., Kaiser, J. F., Mattern, D., Urban, N. D., Henke, M., & Blau, C. A. (2009) · Stem Cells · doi:10.1002/stem.156 · Cited by 38
Erythropoiesis-Stimulating Agent Use in Cancer: Preclinical and Clinical Perspectives
Arcasoy, M. O. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0264 · Cited by 38
Self-citationRecombinant human erythropoietin in oncology: current status and further developments
Engert, A. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi307 · Cited by 36
Charu, V., Belani, C. P., Gill, A. N., Bhatt, M., Tomita, D. K., Rossi, G., & Ben-Jacob, A. (2007) · The Oncologist · doi:10.1634/theoncologist.12-6-727 · Cited by 33
Tsuboi, M., Ezaki, K., Tobinai, K., Ohashi, Y., & Saijo, N. (2009) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyn151 · Cited by 29
Hernández, E., Ganly, P. S., Charu, V., DiBenedetto, J., Tomita, D. K., Lillie, T., Taylor, K. M., & for the ARANESP 20030232 Study Group (2009) · Current Medical Research and Opinion · doi:10.1185/03007990903084164 · Cited by 23
Charu, V., Saidman, B. H., Ben-Jacob, A., Justice, G. R., Maniam, A. S., Tomita, D. K., Rossi, G., Rearden, T. P., & Glaspy, J. A. (2007) · The Oncologist · doi:10.1634/theoncologist.12-10-1253 · Cited by 18
Vecchio, M. D., Gattinoni, L., Lozza, L., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.02.059 · Cited by 17
Heras, P., Kritikos, K., Hatzopoulos, A., & Mitsibounas, D. (2008) · European Journal of Cancer Care · doi:10.1111/j.1365-2354.2007.00892.x · Cited by 7
Volgger, B., Petru, E., Angleitner-Boubenizek, L., Weigert, M., Reinthaller, A., Lass, H., Stempfl, A., Gamper, C., Deibl, M., & Marth, C. (2008) · PubMed · Cited by 3
Cited by
Stem-cell-based, tissue engineered tracheal replacement in a child: a 2-year follow-up study
Elliott, M. J., De Coppi, P., Speggiorin, S., Roebuck, D., Butler, C. R., Samuel, E., Crowley, C., McLaren, C., Fierens, A., Vondrys, D., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60737-5 · Cited by 479
KDIGO clinical practice guidelines for bisphosphonate treatment in chronic kidney disease
Woo, K. T., & Chan, C. M. (2011) · Kidney International · doi:10.1038/ki.2011.202 · Cited by 412
Palumbo, A., Rajkumar, S. V., San Miguel, J. F., Larocca, A., Niesvizky, R., Morgan, G., Landgren, O., Hajek, R., Einsele, H., Anderson, K. C., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.48.7934 · Cited by 392
Guidelines on the diagnosis and treatment of iron deficiency across indications: A systematic review
Peyrin-Biroulet, L., Williet, N., & Cacoub, P. (2015) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.114.103366 · Cited by 328
Renal association clinical practice guideline on Anaemia of Chronic Kidney Disease
Mikhail, A., Brown, C., Williams, J. A., Mathrani, V., Shrivastava, R., Evans, J., Isaac, H., & Bhandari, S. (2017) · BMC Nephrology · doi:10.1186/s12882-017-0688-1 · Cited by 299
Metadata
- Authors
- Rizzo, J. D., Brouwers, M., Hurley, P., Seidenfeld, J., Arcasoy, M. O., Spivak, J. L., Bennett, C. L., Bohlius, J., Evanchuk, D., Goode, M. J., Jakubowski, A. A., Regan, D. H., & Somerfield, M. R.
- Venue
- Journal of Clinical Oncology
- Published
- 2010-11-20
- Volume
- 28
- Issue
- 33
- Pages
- 4996-5010
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2140391009
- Cited by
- 303
- References
- 90
- FWCI
- 23.52
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.